Journal Article (Review Article)

DZNE-2024-01079

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png In vivo detection of Alzheimer's and Lewy body disease concurrence: Clinical implications and future perspectives.

Baiardi, S. ; Hansson, O. ; Levin, J.DZNE* ; Parchi, P.

2024
Wiley Hoboken, NJ

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/alz.14039

Abstract: The recent introduction of seed amplification assays (SAAs) detecting misfolded α-synuclein, a pathology-specific marker for Lewy body disease (LBD), has allowed the in vivo identification and phenotypic characterization of patients with co-occurring Alzheimer's disease (AD) and LBD since the early clinical or even preclinical stage.We reviewed studies with an in vivo biomarker-based diagnosis of AD-LBD copathology.Studies in large cohorts of cognitively impaired individuals have shown that cerebrospinal fluid (CSF) biomarkers detect the coexistence of AD and LB pathology in approximately 20%-25% of them, independently of the primary clinical diagnosis. Compared to those with pure AD, AD-LBD patients showed worse global cognition, especially in attentive/executive and visuospatial functions, and worse motor functions. In cognitively unimpaired individuals, concurrent AD-LBD pathologies predicted longitudinal cognitive progression with faster worsening of global cognition, memory, and attentive/executive functions.Future research studies aiming for a better precision medicine approach should develop SAAs further to reach a quantitative evaluation or staging of each underlying pathology using a single biofluid sample.α-Synuclein seed amplification assays (SAAs) provide a specific marker for Lewy body disease (LBD). SAAs allow for the in vivo identification of co-occurring LBD in patients with Alzheimer's disease (AD). AD-LBD coexist in 20-25% of cognitively impaired elderly individuals, and ∼8% of those asymptomatic. Compared to pure AD, AD-LBD causes a faster worsening of cognitive functions. AD-LBD is associated with worse attentive/executive, memory, visuospatial and motor functions.

Keyword(s): Humans (MeSH) ; Lewy Body Disease: cerebrospinal fluid (MeSH) ; Lewy Body Disease: diagnosis (MeSH) ; Alzheimer Disease: cerebrospinal fluid (MeSH) ; Alzheimer Disease: diagnosis (MeSH) ; Biomarkers: cerebrospinal fluid (MeSH) ; alpha-Synuclein: cerebrospinal fluid (MeSH) ; Disease Progression (MeSH) ; Lewy body disease ; RT‐QuIC ; dementia ; prions ; real‐time quaking‐induced conversion ; synuclein ; Biomarkers ; alpha-Synuclein

---

Contributing Institute(s):

1. Clinical Neurodegeneration (AG Levin)
2. Clinical Research (Munich) (Clinical Research (Munich))

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2024

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---